Wall Street had a good week. UnitedHealth Group reported Q1 2026 earnings, beat expectations, and the stock jumped roughly 8%. Analysts nodded approvingly. The numbers held up.[1]
And buried in that press release — if you knew where to look — was one of the clearest illustrations of how vertically integrated healthcare actually works, who it’s optimized for, and why it’s now under federal antitrust scrutiny.
The Beat That Tells You Nothing
The headline number was fine: adjusted EPS of $7.23, total revenues of $111.7 billion.[1] The insurance arm is stabilizing after two rough years. The market rewarded the discipline.
But here’s the sentence from the earnings release that deserves more attention than it got:
OptumRx — the PBM arm, the entity that manages prescription drug benefits for tens of millions of Americans — saw adjusted script volume fall to 383 million in Q1 2026, down from 408 million in Q1 2025. A 6% drop in prescriptions processed.[2]
The company’s explanation: *“lower volume from membership attrition at UHC."*[2]
Read that again. The PBM processed fewer prescriptions because the insurance company lost members.
That’s not a coincidence. That’s the architecture.
What a Flywheel Is, and What Happens When It Slows
UnitedHealth Group has spent the better part of two decades building what it calls — and what analysts call — a “flywheel.” The idea: UnitedHealthcare (the insurer) feeds members into Optum (the services arm). Optum’s scale makes it better, cheaper, more data-rich. That makes the insurance product more attractive. Which brings in more members. Which feeds more volume into Optum. Around and around.
OptumRx is the prescription drug spoke on that wheel. When you’re insured by UnitedHealthcare and your employer uses OptumRx as its PBM — and tens of millions of Americans are in exactly this situation — OptumRx isn’t competing for your business. It was assigned your business. It arrives with your insurance card.
So when UnitedHealthcare shed 965,000 Medicare Advantage members in Q1 2026 — a deliberate decision to exit unprofitable enrollees as the company tried to repair its margins — OptumRx lost those customers too.[2] Automatically. Without a competitive process. Without those members ever choosing a different PBM. They just… evaporated from the books.
That’s what vertical integration looks like from the inside of a quarterly filing.
What Employers Are Actually Buying
If your company uses OptumRx to manage employee pharmacy benefits, here is the thing the sales pitch doesn’t say plainly: you are not buying a neutral service. You are buying a business unit of UnitedHealth Group — a company whose interests at any given moment may be centered on its insurance margins, its data division, its physician group revenues, or some combination of all three.
OptumRx’s job, officially, is to manage drug costs on your behalf. Its actual incentive structure runs up a corporate org chart that terminates at a parent whose Q1 operating priorities just caused OptumRx to lose 25 million prescriptions worth of volume.[2] That volume loss didn’t happen because you fired them. It happened because the insurance arm made a business decision you had no part in — and the PBM arm absorbed the consequences automatically.
That’s not how a vendor relationship is supposed to work. A vendor’s performance should be tied to your outcomes. This one is tied to someone else’s.
The formulary your employees use — the list that determines which drugs are covered, which require prior authorization, which land in the expensive tier — was built by an entity that also owns the insurer deciding those prior authorization requests. Your PBM and your employees’ insurer are, in a meaningful number of large employer arrangements, subsidiaries of the same parent. They share data. They share strategic objectives. They do not share your employees’ interests, except incidentally.
For an employee filling a prescription, the conflict is even more direct. Your PBM wasn’t chosen because it was the best at keeping your costs down. It was bundled into your benefits package because your employer’s insurer and the PBM wear the same jersey. Your copay tiers, your covered drugs, your specialty pharmacy options — all of that was shaped by an entity whose primary accountability runs not to you, but to UnitedHealth Group’s next earnings call.
Why the Government Is Paying Attention (And Why You Should Too)
The Department of Justice has been investigating UnitedHealth Group’s structure since at least 2024, and filed a formal antitrust lawsuit in late 2025.[3] The FTC has been running a parallel inquiry into PBM practices broadly.
Here’s the plain-language version of what they’re looking at: when the same company controls your insurer, your PBM, your specialty pharmacy, and — in many markets — your primary care doctor, it doesn’t need to beat competitors. It just needs to make sure you can’t easily leave. Data flows internally. Referrals flow internally. Revenue flows internally. The question regulators are asking is whether that structure serves patients and employers — or whether it’s a machine designed to serve itself.[3]
The quarterly numbers are one answer. OptumRx’s operating earnings fell year-over-year not because it lost a competitive bid, but because a related division made a strategic retreat.[2] That’s the flywheel in reverse. It’s also, arguably, the clearest demonstration of the conflict regulators have been trying to articulate in legal filings: your PBM’s performance is downstream of decisions you never made, by people who don’t work for you.
What Employers and Employees Both Should Care About
OptumRx added over 800 new clients in Q1.[4] The company was quick to note that. It’s winning external business, building toward a version of OptumRx that isn’t wholly dependent on UnitedHealthcare’s membership decisions.
That’s a real strategic imperative — and it’s worth watching. Because if OptumRx can build sufficient external volume, the structural argument that it’s inseparable from the insurer becomes harder to sustain legally, and the flywheel narrative gets rehabilitated for a new audience.
Whether that external growth is coming from employers who understand the conflict of interest they’re buying into — or employers who don’t — is a different question.
Wall Street got its beat. You got a window into something regulators have been describing in legal filings for the better part of a year: a machine built not to optimize your drug costs, but to optimize the returns of the largest healthcare conglomerate in American history.
Those aren’t the same thing. They were never the same thing. And now the quarterly numbers say so plainly.
Sources
- UnitedHealth Group Q1 2026 Earnings Call Highlights — GuruFocus, April 2026. https://www.gurufocus.com/news/8808335/unitedhealth-group-inc-unh-q1-2026-earnings-call-highlights-strong-eps-and-ai-investments-drive-growth
- UnitedHealth Group Reports First Quarter 2026 Results — Business Wire / SEC Form 8-K, April 20, 2026. https://www.sec.gov/Archives/edgar/data/0000731766/000073176626000121/earningsrelease1q26press.htm
- The End of the Flywheel? DOJ Intensifies Structural Challenge Against UnitedHealth’s Vertical Empire — Wedbush/Market Minute, April 8, 2026. https://investor.wedbush.com/wedbush/article/marketminute-2026-4-8-the-end-of-the-flywheel-doj-intensifies-structural-challenge-against-unitedhealths-vertical-empire
- UnitedHealth Group Q1 2026 Earnings Beat All Forecasts — DistilINFO, April 2026. https://distilinfo.com/2026/04/22/unitedhealth-group-q1-2026-earnings-beat-all-forecasts/